Phaseline

Companies › Lumicell

Lumicell: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LUM015
Far-red fluorescent imaging agent
–Phase 1Colorectal CancerDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT02584244LUM015Phase 1Colorectal CancerOncologyDec 2026

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.